Researchers found that a new diagnostic test called the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay can significantly improve the detection of metastatic central nervous system (CNS) cancers. This test is now covered by Blue Shield of California, which expands access to millions more people. The CNSide assay allows for earlier and more accurate identification of cancer cells in the cerebrospinal fluid, which can lead to quicker treatment decisions and better outcomes for patients with leptomeningeal metastases.

This development is important for anyone concerned about brain health or dealing with difficult-to-diagnose cancers. The CNSide test has shown high sensitivity (92%) and specificity (95%), meaning it can accurately identify cancer cells while minimizing false positives. With over 11,000 tests performed at more than 120 cancer institutions in the U.S. since its launch, the test has influenced treatment decisions in 90% of cases. Importantly, earlier detection has been linked to a reduction in healthcare costs related to leptomeningeal metastases by about 40%, demonstrating a tangible benefit for patients and the healthcare system.

The evidence supporting the CNSide assay comes from multiple peer-reviewed studies and the FORESEE clinical trial, which provide strong backing for its clinical utility. However, while the test is now available through various healthcare providers, it is still in the early stages of widespread adoption. As more oncology centers begin to use the CNSide assay, it could become a standard part of diagnosing and managing CNS cancers.

Source: globenewswire.com